Drug for advanced colorectal cancer gets marketing nod in Canada
18 September,2005: Erbitux (Cetuximab) injection as a treatment for metastatic colorectal
Advanced prostate cancer therapy Provenge seeks marketing nod in US
18 September,2005; Dendreon Corporation plans to submit a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to market its investigational immunotherapy Provenge, for the
treatment of advanced prostate
New kidney cancer drug seeks EU nod
13 September,2005: The approval to market a new kidney cancer drug sorafenib has been sought in Europe.
Breast cancer drug Aromasin approved in Europe: Pfizer
15 Sep, 2005:
Pfizer has received European approval to market exemestane tablets (Aromasin) for treating breast cancer in post-menopausal women.
Lung cancer vaccine trials promising: Introgen
13 September,2005: Results from an ongoing trial of cancer vaccine for advanced small cell lung cancer are encouraging, Introgen Therapeutics, Inc reported.
Rituxan, cancer drug can treat rheumatoid arthritis
2 September, 2005: Approval has been sought from the U.S. Food and Drug Administration (FDA) for a new indication for the cancer drug Rituxan
(Rituximab) in patients with active rheumatoid arthritis (RA).
Novartis’ drug for breast cancer recurrence to be given priority review in US
31 August, 2005: The US drugs authority has granted priority review to Femara
(letrozole) as a post surgery treatment in breast cancer.
New cancer combo therapy results
25 August, 2005: OXiGENE, Inc., has presented updated clinical trial data for its lead vascular disruption agent, Combretastatin A4 Prodrug (CA4P).
Cell Therapeutics to seek approval for lung cancer therapy in US and Europe
25 August, 2005: Cell Therapeutics, Inc. (CTI) has plans to seek approval for its lung cancer drug Xyotax in the United States and Europe.
Aspirin stops colon cancer, but may trigger bleeding
24 August, 2005: Aspirin use in long term may help ward off colon cancer, but it may require high doses, but such high aspirin doses may trigger gastro-intestinal bleeding.
Skin disease drug turns into anti-tumor therapy for cancer
22 August, 2005: A clinical stage drug that has been safely used for more than 50 years as a treatment for an infectious skin disease, can now act as a novel anti-tumor therapy for cancer.
"Breast cancer chances higher due to fried chips"
22 August, 2005: Eating fried chips at a young age may increase the chances of contracting breast cancer as an adult, shows research in the US.
Pfizer files NDA for Sutent in US
13th August,2005:Pfizer Inc has submitted a New Drug Application for its cancer medicine SU11248
(sunitinib malate), known as Sutent
Alcohol linked cancers: Acetaldehyde in spot light
10 August, 2005: Researchers probing the link between drinking alcoholic beverages and an increased risk of upper gastrointestinal cancer and other types of cancer, have focused on acetaldehyde, a suspected carcinogen formed as the body metabolizes alcohol.
More funding for Sentinel Breastscan
5 August, 2005: Infrared Sciences Corporation (“ISC”) has announced that it has completed a $2.1 million Series B Preferred Stock financing, acquiring the capital necessary to continue introducing Sentinel BreastScan to a broader market of doctors and patients.
Chemokine gets US patent for novel cancer drug
20 June, 2005: Biotechnology major Chemokine Therapeutics Corporation has received US patent for use of its anti-cancer compound, CTCE-9908.
Prohibitive costs mar cancer therapy
15 July, 2005: Costs of certain new line therapies against cancer are exorbitantly high, even though these drugs offer some hope to patients.
may help cure cancer by killing cancer cells
CALGARY, Alberta, June 28 /PRNewswire/ --
Researchers are now investigating how to make
cancer cells "terminally ill" by giving
a common reovirus to patients with various types
detector may improve on Pap Smears
CHERRY HILL, N.J., June 28 /PRNewswire/ -- Physicians may soon give their patients immediate
and accurate results during a routine pap smear exam designed to screen for any abnormalities in
Novartis has better breast cancer treatment
Toronto, Ontario, April 11, 2005: For the first time, Canadian women have a treatment option to reduce the threat of breast cancer beyond the five years of current standard tamoxifen therapy.
Roche, Novartis lead on novel cancer therapies
23 July, 2005: Swiss pharmaceutical companies Roche and Novartis are riding on the reputation with novel cancer treatments while pharmaceutical giants Merck and Pfizer are more reliant on marketing blockbuster primary care drugs, according to market analysts' reports.
Pfizer's investigational drug reduces tumor growth
14 May, 2005: New Data Show Pfizer’s SUTENT/SU11248
(sunitinib malate) Extends Overall Survival in Gleevec-Resistant GIST
Sugar-free pill Actiq for cancer pain